Research and Markets: Acute Lymphocytic Leukemia (ALL) Therapeutics - Pipeline Assessment and Market Forecasts to 2017

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/1f417a/acute_lymphocytic) has announced the addition of GlobalData's new report "Acute Lymphocytic Leukemia (ALL) Therapeutics - Pipeline Assessment and Market Forecasts to 2017" to their offering.

Acute Lymphocytic Leukemia (ALL) Therapeutics - Pipeline Assessment and Market Forecasts to 2017

GlobalData, the industry analysis specialist, has released its new report, Acute Lymphocytic Leukemia (ALL) Therapeutics - Pipeline Assessment and Market Forecasts to 2017. The report is an essential source of information and analysis on the global ALL market. The report identifies the key trends shaping and driving the global ALL market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global ALL sector.

GlobalData estimates the major markets (the US, the UK, Italy, Spain, France, Germany and Japan) for acute lymphocytic leukemia (ALL) therapeutics was valued at $427.6m in 2010 and forecasts it to grow at a Compound Annual Growth Rate (CAGR) of 2.9% to reach $524.0m by 2017. This growth is primarily attributed to the expected launch of Phase III pipeline candidates Marqibo (vincristine sulfate liposomes injection), GRASPA (asparaginase loaded into erythrocytes), recombinant asparaginase (asparaginase) and Depocyt (liposomal cytarabine) during the forecast period. The moderate growth rate is primarily attributed to the patent expiry of Gleevec in 2015 in the US; 2016 in Europe, Clolar in 2015 in Europe and Arranon in 2017 in US; 2013 in Europe.

Key Topics Covered:

1. Table of contents

2. Acute Lymphocytic Leukemia (ALL) Therapeutics - Introduction

3. Acute Lymphocytic Leukemia (ALL) Therapeutics - Market Characterization

4. Acute Lymphocytic Leukemia (ALL) Therapeutics - Competitive Assessment

5. Acute Lymphocytic Leukemia (ALL) Therapeutics - Pipeline Assessment

6. Acute Lymphocytic Leukemia (ALL) Therapeutics - Clinical Trials Mapping

7. Acute Lymphocytic Leukemia (ALL) Therapeutics - Strategic Assessment

8. Acute Lymphocytic Leukemia (ALL) Therapeutics - Future Players

9. Acute Lymphocytic Leukemia (ALL) Therapeutics - Licensing & Partnership Deals

10. Acute Lymphocytic Leukemia (ALL) Therapeutics - Appendix

Companies Mentioned:

  • Erytech Pharma
  • Talon Therapeutics Inc

For more information visit http://www.researchandmarkets.com/research/1f417a/acute_lymphocytic



CONTACT:

Research and Markets
Laura Wood, Senior Manager
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
[email protected]

KEYWORDS:   United Kingdom  United States  Europe  Asia Pacific  North America  Japan

INDUSTRY KEYWORDS:   Health  Oncology  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

Six pharmaceutical execs are set to head to Washington next week for pricing hearings at the House Committee on Oversight and Reform. 

After sifting through the data, one analyst figures the latest Opdivo-Keytruda showdown in kidney cancer might come down to commercial execution.

Biogen is giving former chief finance officer Jeff Capello a multimillion-dollar cash payment plus other severance benefits.